Global alternative asset manager, The Carlyle Group (NASDAQ: CG), today announced the appointment of Jesse Wu, former Chairman of Johnson & Johnson China and former Worldwide Chairman of the Johnson & Johnson Consumer Group, as a Senior Advisor to the group’s Asia buyout team. Mr. Wu brings to Carlyle nearly 30 years of experience in the healthcare and related sectors.

Mr. X.D. Yang, Managing Director and Co-Head of the Carlyle Asia buyout team, said, “We are thrilled to welcome Jesse Wu, a global business leader and experienced healthcare expert, as an advisor to Carlyle. With his deep healthcare industry expertise and highly respected senior management capabilities, Jesse will be a great resource for our team and our portfolio companies as we continue to expand our investments in the fast-growing healthcare sector and other related industries in China and across Asia. Our buyout team in Asia has been a leader in investing in healthcare with more than $1.3 billion of equity invested in seven companies across the Asia-Pacific region and we remain greatly excited about future investment opportunities.”

Mr. Wu said, “I am delighted to work with The Carlyle Group. Having been in the healthcare industry for almost three decades, I see fundamental changes happening in this space, ranging from changing demographic trends to more favorable regulatory reforms, as well as exciting, new technologies and treatments. I look forward to engaging with the team and leveraging my industry experience to advise on attractive investment opportunities and help create value for Carlyle’s portfolio of companies.”

Mr. Wu joined Johnson & Johnson in 1989 and served as Chairman of Johnson & Johnson China and as a member of the company’s management committee from 2013 to 2016. During his 26-year tenure at Johnson & Johnson, Mr. Wu served across multiple roles, including as Worldwide Chairman of the Johnson & Johnson Consumer Group and Company Group Chairman for Global Markets.

The Carlyle Asia buyout team has extensive experience in the rapidly growing healthcare sector in the Asia-Pacific region, excluding Japan. To date, the team has invested more than $1.3 billion of equity in seven companies. Its recent and historical investments include Meinian Onehealth, Zhongmei Healthcare, MicroPort Scientific Corporation, and Haier Bio-Medical and Laboratory Products in China; Global Health and Metropolis Healthcare in India; and Healthscope in Australia. Globally, Carlyle has invested more than $8.4 billion of equity in over 50 investments in the healthcare sector.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $178 billion of assets under management across 125 funds and 164 fund of funds vehicles as of March 31, 2016. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation.